alexa Basiliximab for the treatment of steroid-resistant ulcerative colitis: further experience in moderate and severe disease.
Immunology

Immunology

Journal of Clinical & Cellular Immunology

Author(s): Creed TJ, Probert CS, Norman MN, Moorghen M, Shepherd NA,

Abstract Share this page

Abstract BACKGROUND: Preliminary data have suggested that interleukin-2 receptor blockade with basiliximab may increase steroid sensitivity. We have previously reported a small case series demonstrating the potential of basiliximab as a novel agent for the treatment of steroid-resistant ulcerative colitis. AIM: To report further experience of the efficacy and safety of treatment with the interleukin-2 receptor blocking monoclonal antibody basiliximab, in addition to steroids, for the treatment of severe and moderate steroid-resistant ulcerative colitis. METHODS: Twenty patients were enrolled - 13 patients with moderate steroid-resistant ulcerative colitis (Ulcerative Colitis Symptom Score: >or=6) and seven patients with severe steroid-resistant ulcerative colitis. All were given a single dose of 40 mg basiliximab plus standard steroid therapy in an open-label, uncontrolled trial. Primary end point was clinical remission within 8 weeks (Ulcerative Colitis Symptom Score:
  • DOI: 10.1111/j.1365-2036.2006.02904.x
  • This article was published in Aliment Pharmacol Ther and referenced in Journal of Clinical & Cellular Immunology

    Relevant Expert PPTs

    Relevant Speaker PPTs

    Recommended Conferences

    Relevant Topics

    Peer Reviewed Journals
     
    Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
    International Conferences 2017-18
     
    Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

    Contact Us

     
    © 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
    adwords